CVS' Health Services segment posts $43B in revenues as specialty pharmacy and Caremark deals drive 2025 growth prospects.

Valuation also favors CVS. While UNH trades at a forward P/E of 12.98X, CVS trades at a more modest 10.31. This valuation gap ...

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

CVS Health CVS has seen its stock surge by 53.7% in 2025, fueled by a potent combination of strong operational performance ...

A law firm has filed a class-action lawsuit, accusing CVS of using patient information to send political texts ...

Eli Lilly and Company (NYSE:LLY) may be affected by the CVS formulary change considering it could change how its medication, Zepbound, is viewed when compared to Wegovy. That said, despite possible ...

However, it is not the first alliance between the two companies. COVID accelerated coalitions In 2008, CVS Caremark, a prescription benefit management company, signed on to use Microsoft's ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price cut with the company, along with Novo ...